Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 20/20 | 0.83 |
| ▸ | SLC6A2 | P23975 | 9/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.47 |
| ▸ | HTR2A | P28223 | 5/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5878711 | 0.91 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3HTR2AKCNH2 | |
| SCHEMBL5878721 | 0.75 | SLC6A4 (0.72) | SLC6A4SLC6A2HTR2AKCNH2 | |
| SCHEMBL7207929 | 0.74 | SLC6A4 (0.53) | SLC6A4SLC6A2SLC6A3HTR2AKCNH2 | |
| SCHEMBL7207921 | 0.74 | SLC6A4 (0.53) | SLC6A4SLC6A2SLC6A3HTR2AKCNH2 | |
| SCHEMBL7207176 | 0.74 | SLC6A4 (0.53) | SLC6A4SLC6A2SLC6A3HTR2AKCNH2 | |
| SCHEMBL7207167 | 0.72 | SLC6A4 (0.69) | SLC6A4SLC6A2SLC6A3HTR2AKCNH2 | |
| SCHEMBL5878703 | 0.71 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3HTR2AKCNH2 | |
| SCHEMBL5878517 | 0.70 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3HTR2AKCNH2 | |
| SCHEMBL5878577 | 0.70 | SLC6A4 (0.78) | SLC6A4SLC6A2SLC6A3HTR2AKCNH2 | |
| SCHEMBL5878679 | 0.70 | SLC6A4 (0.78) | SLC6A4SLC6A2SLC6A3HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7129234-B2 | Phenyl heterocyclyl ethers | PFIZER INC. (US) | 2006-10-31 | — | — | US | disclosed |
| EP-1377550-B9 | PHENYL HETEROCYCLYL ETHER DERIVATIVES AS SEROTONIN RE-UPTAKE INHIBITORS | PFIZER LTD (GB) | 2005-11-23 | — | — | EP | disclosed |
| EP-1377550-B1 | PHENYL HETEROCYCLYL ETHER DERIVATIVES AS SEROTONIN RE-UPTAKE INHIBITORS | PFIZER LTD (GB) | 2004-11-03 | — | — | EP | disclosed |
| US-20040106594-A1 | Phenyl heterocyclyl ethers | PFIZER INC | 2004-06-03 | — | — | US | disclosed |
| US-20030207857-A1 | Phenyl heterocyclyl ethers | PFIZER INC. | 2003-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207857-A1 | Phenyl heterocyclyl ethers | CYP2E1, CYP1A1, CCNI | SLC6A4 3835/4885SLC6A2 4120/4885SLC6A3 3857/4885 |
| US-20040106594-A1 | Phenyl heterocyclyl ethers | CYP2E1, CYP1A1, CCNI | SLC6A4 3835/4885SLC6A2 4120/4885SLC6A3 3857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.